The interactions between the sympathetic nervous system (SNS) and angiotensin II (ANG II), and their direct effects in vitro on the enzymes involved in vascular extracellular matrix (ECM) degradation, were examined.
Rats were treated with guanethidine, losartan or the combined treatments. mRNA, protein and activity of matrix metalloproteinase (MMP)-2 and MMP-9 and mRNA of tissue plasminogen activator (t-PA) and plasminogen activator inhibitor 1 (PAI-1) were quantified in abdominal aorta (AA) and femoral artery (FA). Norepinephrine (NE) or ANG II with adrenergic (β, α1 and α2) or losartan antagonists was tested for MMP mRNA response in cultured vascular smooth muscle cells (VSMCs).
Combined treatment enhances the inhibition of MMP-2 mRNA and protein level induced by simple treatment in AA. However MMP-9 in AA and MMP mRNA in FA were reduced in the same order by treatments. MMP activities were not affected by treatments. The t-PA/PAI-1 ratio, which reflects the fibrinolytic balance, remained higher after treatments. In cultured VSMCs, NE induced stimulation of MMP mRNA via α2 and β adrenergic receptors and MMP-2 activity via β adrenergic receptors, while ANG II-induced stimulation was abrogated by losartan.
Overall, there is a synergic inhibition of both systems on the level of MMP-2 in AA.
JacobMP. Extracellular matrix remodeling and matrix metalloproteinases in the vascular wall during aging and in pathological conditions. Biomed Pharmacother2003; 57: 195–202.
2.
FondardODetaintDIungBChoqueuxCAdle-BiassetteHJarrayaM. Extracellular matrix remodelling in human aortic valve disease: the role of matrix metalloproteinases and their tissue inhibitors. Eur Heart J2005; 26: 1333–1341.
3.
NagaseHBrewK. Designing TIMP (tissue inhibitor of metalloproteinases) variants that are selective metalloproteinase inhibitors. Biochem Soc Symp2003; (70): 201–212.
4.
MalemudCJ. Matrix metalloproteinases: role in skeletal development and growth plate disorders. Front Biosci2006; 11: 1702–1715.
5.
GalisZSKhatriJJ. Matrix metalloproteinases in vascular remodeling and atherogenesis: the good, the bad, and the ugly. Circ Res2002; 90: 251–262.
6.
GoodfieldNENewbyDELudlamCAFlapanAD. Effects of acute angiotensin II type 1 receptor antagonism and angiotensin converting enzyme inhibition on plasma fibrinolytic parameters in patients with heart failure. Circulation1999; 99: 2983–2985.
7.
LijnenHR. Elements of the fibrinolytic system. Ann N Y Acad Sci2001; 936: 226–236.
NewbyAC. Dual role of matrix metalloproteinases (matrixins) in intimal thickening and atherosclerotic plaque rupture. Physiol Rev2005; 85: 1–31.
10.
WynnTA. Cellular and molecular mechanisms of fibrosis. J Pathol2008; 214: 199–210.
11.
UngerTLiJ. The role of the renin-angiotensin-aldosterone system in heart failure. J Renin Angiotensin Aldosterone Syst2004; 5 (Suppl 1): S7–10.
12.
WangTLYangYHChangHHungCR. Angiotensin II signals mechanical stretch-induced cardiac matrix metalloproteinase expression via JAK-STAT pathway. J Mol Cell Cardiol2004; 37: 785–794.
13.
StacyLBYuQHorakKLarsonDF. Effect of angiotensin II on primary cardiac fibroblast matrix metalloproteinase activities. Perfusion2007; 22: 51–55.
14.
DendorferARaaschWTempelKDominiakP. Interactions between the renin-angiotensin system (RAS) and the sympathetic system. Basic Res Cardiol1998; 93: 24–29.
15.
BaltJCMathyMJNapAPfaffendorfMvan ZwietenPA. Effect of the AT1-receptor antagonists losartan, irbesartan, and telmisartan on angiotensin II-induced facilitation of sympathetic neurotransmission in the rat mesenteric artery. J Cardiovasc Pharmacol2001; 38: 141–148.
16.
CoxSLBenAStoryDFZiogasJ. Evidence for the involvement of different receptor subtypes in the pre- and postjunctional actions of angiotensin II at rat sympathetic neuroeffector sites. Br J Pharmacol1995; 114: 1057–1063.
17.
WangMZhangJSpinettiGJiangLQMonticoneRZhaoD. Angiotensin II activates matrix metalloproteinase type II and mimics age-associated carotid arterial remodeling in young rats. Am J Pathol2005; 167: 1429–1442.
18.
DabHHachaniRHodrojWSaklyMBriccaGKacemK. Differential control of MMP and t-PA/PAI-1 expressions by sympathetic and renin-angiotensin systems in rat left ventricle. Auton Neurosci2009; 150: 27–32.
19.
CeruttiCKurdiMBriccaGHodrojWPaultreCRandonJ. Transcriptional alterations in the left ventricle of three hypertensive rat models. Physiol Genomics2006; 27: 295–308.
20.
HodrojWLegedzLFoudiNCeruttiCBourdillonMCFeugierP. Increased insulin-stimulated expression of arterial angiotensinogen and angiotensin type 1 receptor in patients with type 2 diabetes mellitus and atheroma. Arterioscler Thromb Vasc Biol2007; 27: 525–531.
ReinhardtDSiguschHHHensseJTyagiSCKörferRFigullaHR. Cardiac remodelling in end stage heart failure: upregulation of matrix metalloproteinase (MMP) irrespective of the underlying disease, and evidence for a direct inhibitory effect of ACE inhibitors on MMP. Heart2002; 88: 525–530.
23.
SupowitSCEthridgeRTZhaoHKatkiKADipetteDJ. Calcitonin gene-related peptide and substance P contribute to reduced blood pressure in sympathectomized rats. Am J Physiol Heart Circ Physiol2005; 289: H1169–H1175.
24.
BorovskyVHermanMDunphyGCapleaAElyD. CO2 asphyxia increases plasma norepinephrine in rats via sympathetic nerves. Am J Physiol1998; 274(1 Pt 2): R19–22.
BasalygaDMSimionescuDTXiongWBaxterBTStarcherBCVyavahareNR. Elastin degradation and calcification in an abdominal aorta injury model: role of matrix metalloproteinases. Circulation2004; 110: 3480–3487.
27.
HeathJWBurnstockG. Selectivity of neuronal degeneration produced by chronic guanethidine treatment. J Neurocytol1977; 4: 397–405.
28.
LeeMHadiMHalldénGAponteGW. Peptide YY and neuropeptide Y induce villin expression, reduce adhesion, and enhance migration in small intestinal cells through the regulation of CD63, matrix metalloproteinase-3, and Cdc42 activity. J Biol Chem2005; 280: 125–136.
29.
YangEVSoodAKChenMLiYEubankTDMarshCB. Norepinephrine up-regulates the expression of vascular endothelial growth factor, matrix metalloproteinase (MMP)-2, and MMP-9 in nasopharyngeal carcinoma tumor cells. Cancer Res2006; 66: 10357–10364.
30.
WuTCChenYHLeuHBChenYLLinFYLinSJ. Carvedilol, a pharmacological antioxidant, inhibits neointimal matrix metalloproteinase-2 and -9 in experimental atherosclerosis. Free Radic Biol Med2007; 43: 1508–1522.
31.
SukhovaGKSchönbeckURabkinESchoenFJPooleARBillinghurstRC. Evidence for increased collagenolysis by interstitial collagenases-1 and -3 in vulnerable human atheromatous plaques. Circulation1999; 99: 2503–2509.
32.
LindseyMWedinKBrownMDKellerCEvansAJSmolenJ. Matrix-dependent mechanism of neutrophil-mediated release and activation of matrix metalloproteinase 9 in myocardial ischemia/reperfusion. Circulation2001; 103: 2181–2187.
33.
ChuaCCHamdyRCChuaBH. Angiotensin II induces TIMP-1 production in rat heart endothelial cells. Biochim Biophys Acta1996; 1311: 175–180.
34.
CastoldiGDi GioiaCRPieruzziFD’OrlandoCVan De GreefWMBuscaG. ANG II increases TIMP-1 expression in rat aortic smooth muscle cells in vivo. Am J Physiol Heart Circ Physiol2003; 284: H635–643.
35.
WalterAEtienne-SelloumNSarrMKaneMOBeretzASchini-KerthVB. Angiotensin II induces the vascular expression of VEGF and MMP-2 in vivo: preventive effect of red wine polyphenols. J Vasc Res2008; 45: 386–394.
36.
DingHLXuMTGuoYChenLZhangSLLiF. Effect of losartan on the mRNA expressions of MT3-MMP and TIMP-2 in diabetic kidneys. Rev Diabet Stud2005; 2: 216–220.
